CA3154499A1 - Compositions and methods for rescuing retinal and choroidal structure and function - Google Patents

Compositions and methods for rescuing retinal and choroidal structure and function Download PDF

Info

Publication number
CA3154499A1
CA3154499A1 CA3154499A CA3154499A CA3154499A1 CA 3154499 A1 CA3154499 A1 CA 3154499A1 CA 3154499 A CA3154499 A CA 3154499A CA 3154499 A CA3154499 A CA 3154499A CA 3154499 A1 CA3154499 A1 CA 3154499A1
Authority
CA
Canada
Prior art keywords
hemichannel
retinal
alkyl
subject
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3154499A
Other languages
English (en)
French (fr)
Inventor
Colin Richard Green
Nasir Mat NOR
Monica Liliana Acosta ETCHEBARNE
Bradford James Duft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Inflammx Therapeutics Inc
Original Assignee
Auckland Uniservices Ltd
Ocunexus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd, Ocunexus Therapeutics Inc filed Critical Auckland Uniservices Ltd
Publication of CA3154499A1 publication Critical patent/CA3154499A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3154499A 2019-09-13 2020-09-11 Compositions and methods for rescuing retinal and choroidal structure and function Pending CA3154499A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900379P 2019-09-13 2019-09-13
US62/900,379 2019-09-13
US201962903504P 2019-09-20 2019-09-20
US62/903,504 2019-09-20
PCT/US2020/050579 WO2021051015A1 (en) 2019-09-13 2020-09-11 Compositions and methods for rescuing retinal and choroidal structure and function

Publications (1)

Publication Number Publication Date
CA3154499A1 true CA3154499A1 (en) 2021-03-18

Family

ID=74866757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3154499A Pending CA3154499A1 (en) 2019-09-13 2020-09-11 Compositions and methods for rescuing retinal and choroidal structure and function

Country Status (6)

Country Link
US (1) US20220401408A1 (enExample)
EP (1) EP4027992A4 (enExample)
JP (2) JP2022547324A (enExample)
CN (2) CN114727981B (enExample)
CA (1) CA3154499A1 (enExample)
WO (1) WO2021051015A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025219925A1 (en) * 2024-04-19 2025-10-23 Auckland Uniservices Limited Compounds for treatment and prevention of diseases, disorders and conditions
WO2025219923A1 (en) * 2024-04-19 2025-10-23 Auckland Uniservices Limited Modulators for treatment and prevention of diseases, disorders and conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281524A1 (en) * 2008-06-05 2013-10-24 Peter Blower Novel treatments
EP2506847A1 (en) * 2009-12-03 2012-10-10 Proximagen Limited Treatment of infectious diseases
US10465188B2 (en) * 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
JP6898848B2 (ja) * 2014-09-19 2021-07-07 メモリアル スローン ケタリング キャンサー センター 脳転移を治療するための方法

Also Published As

Publication number Publication date
JP2025181930A (ja) 2025-12-11
EP4027992A1 (en) 2022-07-20
US20220401408A1 (en) 2022-12-22
JP2022547324A (ja) 2022-11-11
CN114727981A (zh) 2022-07-08
CN114727981B (zh) 2026-03-31
WO2021051015A1 (en) 2021-03-18
EP4027992A4 (en) 2023-11-29
CN121846082A (zh) 2026-04-14

Similar Documents

Publication Publication Date Title
Nor et al. Connexin hemichannel block using orally delivered tonabersat improves outcomes in animal models of retinal disease
Huang et al. Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia
JP2025181930A (ja) 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法
HRP20040406A2 (en) Methods for treating ocular neovascular diseases
JP6964708B2 (ja) イオントフォレシスを用いた生物活性分子の眼内送達
Ju et al. Verteporfin-mediated on/off photoswitching functions synergistically to treat choroidal vascular diseases
US20190336482A1 (en) Compositions and methods for treating and diagnosing ocular disorders
US11266710B2 (en) Angio-3 for treatment of retinal angiogenic diseases
EP3448388B1 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
Blair et al. Inner retinal oxygen delivery, metabolism, and extraction fraction in ins2akita diabetic mice
WO2011097577A2 (en) Compositions and methods for treating or preventing retinal degeneration
CA3156220A1 (en) Anti-c5 agent for treatment of dry age-related macular degeneration (amd) or geographic atrophy secondary to dry amd
KR20140041459A (ko) 초기 녹내장에서 정상적인 시각 기능을 회복시키는 ｐａｃａｐ에 기반한 안과용 제제
HK40080560A (en) Compositions and methods for rescuing retinal and choroidal structure and function
US20220280473A1 (en) Compositions and methods for modulating epithelial-mesenchymal transition
WO2024220474A1 (en) Methods of treating age-related macular degeneration targeting igfbpl-1
Hass UCP2-Dependent Changes in Mitochondrial Dynamics Protect the Retina from Glaucoma
CN119907677A (zh) 在治疗黄斑水肿或视网膜静脉阻塞中使用的单体膜联蛋白a5
Delgado‑Tirado et al. www. nature. com/scientificreports OPEN Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy
KR20180089819A (ko) 인돌-3-카비놀 또는 이의 약제학적으로 허용되는 염을 포함하는 당뇨 망막병증의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240910

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240910

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240918

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240918

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240918

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241121

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241202

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241202

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250414

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250704

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250704

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251028

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251218

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20260420